Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) has announced that Eric J. Daniels, M.D., MBA, will resign from his position as Chief Development Officer effective April 17, 2026. The decision to leave was made by Mr. Daniels to pursue another opportunity and was not due to any disagreements regarding the company's operations or policies. Kiora's President and CEO, Brian M. Strem, expressed gratitude for Mr. Daniels' contributions to the company, highlighting his significant impact during his tenure. The company is now in the process of searching for a successor to fill the Chief Development Officer role.

In conjunction with this leadership change, Kiora Pharmaceuticals remains focused on advancing its pipeline of treatments for retinal diseases. The internal clinical development team is actively working on patient enrollment for ongoing clinical trials, including the KIO-301 and KIO-104 studies. Recently, the ABACUS-2 Phase 2 clinical trial for KIO-301 received approval to enroll additional patients in the 50µg dose cohort and to initiate the 100µg dose cohort. Similarly, the KLARITY Phase 2 clinical trial for KIO-104 has cleared all planned safety review checkpoints, and patient enrollment is ongoing.

Kiora Pharmaceuticals is dedicated to developing innovative therapies aimed at addressing critical pathways in retinal diseases, with the goal of slowing, stopping, or restoring vision loss. The company continues to leverage its established network of outsourced clinical research organizations (CROs) to support its development programs. As Kiora navigates this transition in leadership, it remains committed to its strategic objectives and the advancement of its clinical pipeline.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.